hypoparathyroidism

PRAGUE, Czech Republic, May 12, 2026 AstraZeneca and Alexion announced positive Phase III clinical trial results for eneboparatide (AZP-3601),...

SOUTH SAN FRANCISCO, Calif., April 13, 2026 Septerna, Inc. has announced the initiation of its Phase 1 clinical trial...